Stocktoria
Atara Biotherapeutics, Inc. ATRA
Atara Biotherapeutics, Inc. (ATRA) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $120.8M at a 27.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
| GLUE | Monte Rosa Therapeutics, Inc. | 4/9 | 1.67 | — | +63.5% |
| AGEN | AGENUS INC | 2/9 | — | — | +10.4% |
| IBRX | ImmunityBio, Inc. | 4/9 | — | — | +668.3% |
| IPSC | Century Therapeutics, Inc. | 3/9 | -6.53 | — | — |
| STRO | SUTRO BIOPHARMA, INC. | 2/9 | — | — | +65.2% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
FAQ
Is ATRA financially healthy?
Atara Biotherapeutics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does ATRA pay a dividend?
No, Atara Biotherapeutics, Inc. does not currently pay a dividend.
How profitable is ATRA?
In FY2025, Atara Biotherapeutics, Inc. had a net margin of 27.1%.
What is ATRA's P/E ratio?
Atara Biotherapeutics, Inc.'s trailing price-to-earnings (P/E) ratio is about 2.9×, based on its latest annual earnings.
What is the analyst price target for ATRA?
The average Wall-Street price target for Atara Biotherapeutics, Inc. is $13.67, about 48.1% above the recent price, from 3 analysts (consensus: strong buy).
Is ATRA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Atara Biotherapeutics, Inc.: a Piotroski F-score of 4/9, a P/E of about 2.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.